202 related articles for article (PubMed ID: 12420752)
1. Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents.
Scozzafava A; Mastrolorenzo A; Supuran CT
J Enzyme Inhib Med Chem; 2002 Apr; 17(2):69-76. PubMed ID: 12420752
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
3. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
4. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
[TBL] [Abstract][Full Text] [Related]
6. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
8. Targeting CXCR4 in HIV cell-entry inhibition.
Steen A; Schwartz TW; Rosenkilde MM
Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
De Clercq E
Mol Pharmacol; 2000 May; 57(5):833-9. PubMed ID: 10779364
[TBL] [Abstract][Full Text] [Related]
10. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
Scarlatti G; Tresoldi E; Björndal A; Fredriksson R; Colognesi C; Deng HK; Malnati MS; Plebani A; Siccardi AG; Littman DR; Fenyö EM; Lusso P
Nat Med; 1997 Nov; 3(11):1259-65. PubMed ID: 9359702
[TBL] [Abstract][Full Text] [Related]
11. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Bridger GJ; Skerlj RT; Padmanabhan S; Martellucci SA; Henson GW; Struyf S; Witvrouw M; Schols D; De Clercq E
J Med Chem; 1999 Sep; 42(19):3971-81. PubMed ID: 10508445
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of SDF-1/CXCR4-induced Ca2+ signaling by fluorometric imaging plate reader (FLIPR) and flow cytometry.
Princen K; Hatse S; Vermeire K; De Clercq E; Schols D
Cytometry A; 2003 Jan; 51(1):35-45. PubMed ID: 12500303
[TBL] [Abstract][Full Text] [Related]
14. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication.
Bridger GJ; Skerlj RT; Hernandez-Abad PE; Bogucki DE; Wang Z; Zhou Y; Nan S; Boehringer EM; Wilson T; Crawford J; Metz M; Hatse S; Princen K; De Clercq E; Schols D
J Med Chem; 2010 Feb; 53(3):1250-60. PubMed ID: 20043638
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.
Seibert C; Sakmar TP
Curr Pharm Des; 2004; 10(17):2041-62. PubMed ID: 15279544
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists.
Princen K; Hatse S; Vermeire K; De Clercq E; Schols D
Retrovirology; 2004 Mar; 1():2. PubMed ID: 15169555
[TBL] [Abstract][Full Text] [Related]
18. The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells.
Schols D; De Clercq E
J Gen Virol; 1998 Sep; 79 ( Pt 9)():2203-5. PubMed ID: 9747729
[TBL] [Abstract][Full Text] [Related]
19. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.
Maeda K; Yoshimura K; Shibayama S; Habashita H; Tada H; Sagawa K; Miyakawa T; Aoki M; Fukushima D; Mitsuya H
J Biol Chem; 2001 Sep; 276(37):35194-200. PubMed ID: 11454872
[TBL] [Abstract][Full Text] [Related]
20. Co-receptor antagonists as HIV-1 entry inhibitors.
Shaheen F; Collman RG
Curr Opin Infect Dis; 2004 Feb; 17(1):7-16. PubMed ID: 15090884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]